C-Rad AB (CRAD-B) Fair Value & Analysis
Healthcare · SE · Market cap 1.2B SEK
Fair value as of: Jul 16, 2026
From 24 valuation models · updated 6 days ago
Share price +1.6% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 24.82 – kr 38.20 · fair‑value band kr 6.99 – kr 18.58 · the kr 37.50 price screens above the kr 15.50 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
C-Rad AB (CRAD-B) currently trades at kr 37.50, while our model-based Fair Value estimate is kr 15.50, implying the stock looks roughly 58.7% overvalued today. We read business quality at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, C-Rad AB generated revenue of 428M SEK at a net margin of 7.0%. Revenue declined 11.9% year over year. It earns a return on equity of 8.8%. The balance sheet holds a net cash position of 152M SEK. Fundamentals as of Jul 16, 2026
Our scenario range runs from kr 6.99 (bear case) to kr 18.58 (bull case); at kr 37.50, the current price sits above that range. The share trades near its 52-week high and 53% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -59%, CRAD-B screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy solution that supports proton therapy from simulation to treatment; Catalyst+ HD Ring Gantry solution for patient positioning, real-time motion monitoring, and respiratory gating; and Sentinel 4DCT, a laser-based optical surface scanning system. It also provides Catalyst, a 4D surface guided radiation therapy (SGRT) solution; Catalyst HD, a SGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; and visual …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
C-Rad AB reported revenue of kr 442M in FY2025 versus kr 261M in FY2021, a compound +14.1%/yr. Reported net income was kr 10.5M in FY2025, compounding −19.6%/yr from FY2021.
Is CRAD-B fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $86.97 | $69.36 | -20% |
| Stryker Corporation SYK | $305.66 | $187.83 | -39% |
| Medtronic plc MDTC34 | R$210.63 | R$24.08 | -89% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EWL | €75.46 | €37.29 | -51% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
| DexCom, Inc DXCM | $74.77 | $53.93 | -28% |
| GE HealthCare Technologies Inc GEHC | $60.64 | $65.03 | +7% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥143.50 | ¥111.50 | -22% |
| Koninklijke Philips N.V PHG | $26.98 | $10.24 | -62% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is C-Rad AB (CRAD-B) undervalued?
What is the fair value of CRAD-B?
What is the quality score of CRAD-B?
What is the revenue of C-Rad AB (CRAD-B)?
What is the net profit margin of CRAD-B?
Does C-Rad AB pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full C-Rad AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.